Business
Notice of Interim Results
Avacta Group PLC will announce its unaudited interim results for the six months ended June 30, 2025, on September 30, 2025, and will deliver a live presentation via Investor Meet Company at 14:00 BST on the same day. The company also confirmed a change to the date, time, and location for the presentation of its abstract at the European Society for Medical Oncology (ESMO) Congress. The presentation, titled "A Phase I trial of FAP-Dox (AVA6000)..." with abstract number 964P, will now take place on October 19 at 12:00-12:45 in Hall 25. Disclaimer*
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n\nNotice of Interim Results and Investor Presentation\n \nChange of Date, Time and Location of ESMO Abstract Presentation\n \n \nLONDON AND PHILADELPHIA - September 15, 2025 - Avacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, confirms it will announce its unaudited interim results for the six months ended June 30, 2025 (\"HY25\"), on September 30, 2025.\n \nChristina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will also deliver a live presentation via Investor Meet Company at 14:00 BST on the day.\n \nThe presentation is open to all existing and potential shareholders.\n \nInvestors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via: AVCT - AVACTA GROUP PLC | Investor Meet Company\n \nInvestors who already follow Avacta on the Investor Meet Company platform will automatically be invited.\n \nQuestions can be submitted pre-event via the Investor Meet Company dashboard up until September 30 09:00 BST, or at any time during the live presentation.\n \nThe Company will also post the results presentation on its website at the following page: https://avacta.com/investors/investor-resources/.\n \nESMO Congress Update\n \nThe Company confirms that the date, time and location of the abstract being presented at the European Society for Medical Oncology (ESMO) Congress, taking place from October 17-21, 2025, has changed. The updated details are included below:\n \nTitle: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors\nSession Title: Developmental Therapeutics\nSession Date and Time: 19 October, 12.00-12.45\nLocation: Hall 25\nAbstract Presentation Number: 964P\nSpeaker: William D. Tap\n \n-Ends-\n \nFor further information from Avacta, please contact:\n \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\n \n \n\n\n www.peelhunt.com\n \n\n\n\n\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\n \nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\n \n\n\nwww.pan...